Reports from the Field: New drug reduces diabetic cell decline in type 2 patients
Reports from the Field
New drug reduces diabetic cell decline in type 2 patients
A new study finds that pioglitazone hydrochloride, the most recent addition to the thiazolidinedione class of medications, significantly reduces insulin resistance and reduces the decline of pancreatic cell function in type 2 diabetes patients who receive sulfonylurea therapy, according to data presented at the recent 36th annual European Association for the Study of Diabetes meeting in Jerusalem.
The 16-week, placebo-controlled study of 521 patients found that pioglitazone hydrochloride significantly reduced insulin resistance and improved beta cell function when added to the treatment regimen of patients on sulfonylurea therapy at low (15 mg) and intermediate (30 mg) doses. Adding pioglitazone hydrochloride to sulfonylurea therapy resulted in a 30% reduction in insulin resistance and a 38% improvement in beta cell function compared to baseline.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.